Amarin Corp Plc (AMRN)

[NYPharmer1]

Amarin to Present at Lazard Capital Markets Annual Healthcare Conference

DUBLIN and MYSTIC, Conn., Nov. 15, 2010 /PRNewswire via COMTEX/ -- Amarin Corporation plc /quotes/comstock/15*!amrn/quotes/nls/amrn (AMRN 3.46, +0.06, +1.76%) today announced that it is scheduled to present at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 3:10pm. Representing Amarin at this conference will be Joseph Zakrzewski, Chairman and Chief Executive Officer and John Thero, President. This conference will be held at the St. Regis in New York City.

A live audio webcast of the presentation will be available at the following URL:

http://www.wsw.com/webcast/lz8/amrn/

About Amarin

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia on statin therapy. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.

Investor Contact Information:
John F. Thero
President
In U.S.: [phone]
[e-mail]
Lee M. Stern
The Trout Group
In U.S.: [phone]
[e-mail]
Media Contact Information:
David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
In U.S.: [phone] or [phone] (office)
[phone] (mobile)
[e-mail]
[e-mail]
Mark Swallow or David Dible
Citigate Dewe Rogerson
In U.K.: [phone]
[e-mail]